Director

Katsuhiro Uto is responsible for the overall management and strategic direction of FIMECS as the CEO. His professional carrier began at Nippon Boehringer Ingelheim in 2005 as a senior research scientist, before broadening his expertise at two other Japanese specialty pharmaceutical companies. Throughout his carrier, he has been deeply involved in research and development, gaining significant expertise and achieving notable successes in respiratory, immunology, dermatology and pain management fields. He has also led numerous international research collaborations and strategic alliances. In 2021, He joined RaQualia Pharma, and since 2022, he has served as a Board Director, steering the company’s research and development efforts with visionary leadership.

Kanae Gamo is leading overall operations of R&D activities as a CSO. She co-founded FIMECS with her colleagues in 2018 as a curve-out biotech from Takeda Pharmaceutical Company Limited. She started her career at Takeda in 2009. She has expertise in many techniques of molecular biology, genetics, epigenetics and next-generation sequencing in oncology and immunology areas. Through her pharmaceutical experience at Takeda, she increased responsibility of roles across target identification and validation. In parallel with FIMECS work, she got Ph.D. at University of Tsukuba in 2020. Utilizing proprietary drug discovery platform, RaPPIDS, to internal and collaborative programs, FIMECS seeks to provide life-saving medicine to patients all over the world.

Motonori Shimizu serves as the CAO at FIMECS, overseeing the company’s administrative functions. He has extensive experience in human resources and general affairs across multiple companies. At a company of Toyota Tsusho Group, he played a key role as a manager in designing and implementing personnel evaluation and compensation systems. In 2022, he joined RaQualia Pharma, where he led the reforming of the personnel evaluation system and restructuring of the organization as the head of the HR group. In 2025, he was appointed as an Executive Officer in charge of corporate management (current role). In 2025, he joined FIMECS as Vice President of Corporate Development.